Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression
暂无分享,去创建一个
Richard Kay | R. Kay | A. Finlay | F. Dalgard | J. Kupfer | V. Piguet | Faraz Mahmood Ali | Andrew Y Finlay | Vincent Piguet | Joerg Kupfer | Florence Dalgard | M Sam Salek | F. Ali | M. Salek
[1] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[2] T. Kohlmann,et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] Mayte Suárez-Fariñas,et al. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept , 2010, BMC dermatology.
[4] G. Guyatt. Commentary on Jack Dowie, "Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions". , 2002, Health economics.
[5] A. Finlay,et al. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.
[6] Jack Dowie,et al. Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. , 2002, Health economics.
[7] M. Augustin,et al. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities , 2013, Archives of Dermatological Research.
[8] M. Radtke,et al. Willingness‐to‐pay and quality of life in patients with vitiligo , 2009, The British journal of dermatology.
[9] P. Reeves,et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis , 2009, The British journal of dermatology.
[10] M. Sculpher,et al. Alitretinoin for Severe Chronic Hand Eczema , 2012, PharmacoEconomics.
[11] Å. Svensson,et al. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. , 2011, Acta dermato-venereologica.
[12] L. Misery,et al. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries , 2014, The Journal of investigative dermatology.
[13] J. Schmitt,et al. Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis , 2015, Archives of Dermatological Research.
[14] U. Persson,et al. Analysis of three outcome measures in moderate to severe psoriasis: a registry‐based study of 2450 patients , 2012, The British journal of dermatology.
[15] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[16] N. Ikegami,et al. Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.
[17] J. Habbema,et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.
[18] R. Shikiar,et al. Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trial , 2007, The Journal of dermatological treatment.
[19] J. Newton,et al. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. , 2000, Journal of the American Academy of Dermatology.
[20] T. Szucs,et al. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective , 2010, BMC dermatology.
[21] G. Jemec,et al. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values , 2015, Patient related outcome measures.
[22] M. Chren,et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis , 2006, The British journal of dermatology.
[23] M. Ruggeri,et al. The minimum clinically important difference for EQ-5D index: a critical review , 2014, Expert review of pharmacoeconomics & outcomes research.
[24] Oliver Rivero-Arias,et al. Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[25] A. Finlay,et al. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.
[26] J. Szepietowski,et al. Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.
[27] Oliver Rivero-Arias,et al. Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] B. Monz,et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? , 2006, Chest.
[29] A. Finlay,et al. The Role of the EQ-5D in the Economic Evaluation of Dermatological Conditions and Therapies , 2012, Dermatology.
[30] A. Finlay,et al. A systematic review of the use of quality‐of‐life instruments in randomized controlled trials for psoriasis , 2017, The British journal of dermatology.
[31] R. Doughty,et al. Measuring health-related quality of life. , 1999, The New Zealand medical journal.
[32] Leonie Segal,et al. Comparing the Incomparable? A Systematic Review of Competing Techniques for Converting Descriptive Measures of Health Status into QALY-Weights , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.